132 related articles for article (PubMed ID: 21568892)
1. Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.
Brožič P; Turk S; Rižner TL; Gobec S
Curr Med Chem; 2011; 18(17):2554-65. PubMed ID: 21568892
[TBL] [Abstract][Full Text] [Related]
2. Porcine aldo-keto reductase 1C subfamily members AKR1C1 and AKR1C4: Substrate specificity, inhibitor sensitivity and activators.
Endo S; Morikawa Y; Matsunaga T; Hara A; Nishinaka T
J Steroid Biochem Mol Biol; 2022 Jul; 221():106113. PubMed ID: 35398259
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
[TBL] [Abstract][Full Text] [Related]
4. Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism.
Rižner TL; Penning TM
Steroids; 2014 Jan; 79():49-63. PubMed ID: 24189185
[TBL] [Abstract][Full Text] [Related]
5. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
[TBL] [Abstract][Full Text] [Related]
6. Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors.
Chu X; He S; Liu Y; Liu Y; Feng F; Guo Q; Zhao L; Sun H
Chem Biol Interact; 2022 Jan; 351():109746. PubMed ID: 34780792
[TBL] [Abstract][Full Text] [Related]
7. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
8. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
9. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin.
Wang HW; Lin CP; Chiu JH; Chow KC; Kuo KT; Lin CS; Wang LS
Int J Cancer; 2007 May; 120(9):2019-27. PubMed ID: 17266043
[TBL] [Abstract][Full Text] [Related]
10. The roles of aldo-keto reductases in steroid hormone action.
Bauman DR; Steckelbroeck S; Penning TM
Drug News Perspect; 2004 Nov; 17(9):563-78. PubMed ID: 15645014
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
12. Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1.
Brozic P; Cesar J; Kovac A; Davies M; Johnson AP; Fishwick CW; Lanisnik Rizner T; Gobec S
Chem Biol Interact; 2009 Mar; 178(1-3):158-64. PubMed ID: 19007763
[TBL] [Abstract][Full Text] [Related]
13. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1).
El-Kabbani O; Dhagat U; Hara A
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):105-11. PubMed ID: 21050889
[TBL] [Abstract][Full Text] [Related]
15. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
16. Design and development of novel inhibitors of aldo-ketoreductase 1C1 as potential lead molecules in treatment of breast cancer.
Verma P; Hassan MI; Singh A; Singh IK
Mol Cell Biochem; 2021 Aug; 476(8):2975-2987. PubMed ID: 33770316
[TBL] [Abstract][Full Text] [Related]
17. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects.
Davies NJ; Hayden RE; Simpson PJ; Birtwistle J; Mayer K; Ride JP; Bunce CM
Cancer Res; 2009 Jun; 69(11):4769-75. PubMed ID: 19487289
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
[TBL] [Abstract][Full Text] [Related]
19. Aldo-Keto Reductase AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy.
Zeng CM; Chang LL; Ying MD; Cao J; He QJ; Zhu H; Yang B
Front Pharmacol; 2017; 8():119. PubMed ID: 28352233
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of AKR1C inhibitory properties of A-ring halogenated oestrone derivatives.
Sinreih M; Jójárt R; Kele Z; Büdefeld T; Paragi G; Mernyák E; Rižner TL
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1500-1508. PubMed ID: 34227437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
